PCPC3 — the patient-centered prostate cancer collaborative coalition — has just issued a statement about the revised research plan issued by the U.S. Preventive Services Task Force (USPSTF) in reassessing the value of PSA screening for risk of prostate cancer. The full statement is available on the PCPC3 web site. Some of the individual members […]![]()
